USpharma Ltd

Based in the US, USpharma Ltd specializes in the development and commercialization of pharmaceutical products, focusing on brand and pharmaceutically-equivalent offerings to enhance healthcare quality. USpharma Ltd, founded in 2016 and headquartered in Miami Lakes, US, focuses on manufacturing and marketing pharmaceutical products. It has engaged in one deal with 1315 Capital, marking a strategic investment to support its growth. The company was established by a team of industry professionals, bringing extensive experience to its operations.

USpharma Ltd specializes in the development and commercialization of pharmaceutical products, focusing on both brand and pharmaceutically-equivalent offerings. Their core products are designed to address various consumer health and prescription needs, enhancing the quality of healthcare. The company operates a state-of-the-art manufacturing facility to maintain high-quality standards. USpharma’s clientele spans healthcare providers, pharmacies, and direct consumers in North America and select international markets, positioning it prominently within the pharmaceutical sector.

USpharma Ltd generates revenue through structured partnerships and direct sales to retail and wholesale clients, including pharmacies and healthcare facilities. Their revenue streams arise from pharmaceutical product sales, with pricing influenced by market demand and competitive positioning, ensuring they meet diverse client needs. This transactional model reflects USpharma's commitment to delivering healthcare solutions while maintaining sustainable revenue. USpharma Ltd plans to utilize the recent investment from 1315 Capital, finalized in June 2025, to enhance its capabilities and offerings.

The company is working on several new products, with specific launch dates to be announced. USpharma also aims to expand its market reach into additional international regions by 2026, further strengthening its position in the pharmaceutical industry.